🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Agree, conclusion of this study is not appropriate. Unfortunately for pts. #ASCO

Numerical signal does not mean anything anything. It’s a negative study. Unfortunately for patients.

I would not say that Doc wins again. I would say new drugs failed again against Doc, unfortunately for patients.

EVOKE-1 #ASCO24 ; own experience (5th center for inclusions, strangely not in the co-authors);⛔️ for efficacy but also toxicity profil not acceptable for pts, SG vs DOC (%) : diarrhea 52.7 vs 33.7; nausea 41.6 vs 26.0; vomiting 20.9 vs 14.9; pruritus 12.5 vs 3.8; schedule d1d8

So true, knowing that long-term toxicities have also to be considered. But such a big breakthrough !

Krystal12 #ASCO2024; NSCLC ADA > DOC for PFS; toxicities OK. Even if impact of OS is unknown, a new drug in the armamentarium for clinical practice; find the best sequential strategy: 1 ➡️2➡️3; available active new drugs with PFS benefit should at the end increase OS.

FU/FA maintenance therapy with or without panitumumab in RAS WT mCRC #ASCO24 🔎PanaMa, AIO KRK 0212, 378 pts 👉mPFS 8.8 vs. 5.8 mo 👉PFS re-induction 4.1 vs. 7.4 mo 👉TFS17.1 vs 15.1mo 👉mOS 29.9 vs. 24.7 mo 🧐Endpoint met, but no OS benefit -> both option valid ESMO - Eur. Oncology

ASCO #ASCO24 #CRCsm Intriguing phase 2 data from ARC-9 - novel adenosine ⛔️ in refractory MSS mCRC 👉etrumadent +FOLFOX/bev (EZFB) vs rego 📌 n=112, 2:1 📌 OS - 19.6 v 9.5m, HR 0.37! ? contribution of FFX-b 👉need ph3 vs FFX-b 🤔 I may need to revisit rechallenge… OncoAlert

Is FOLFOX +\-Bev as control arm would have been better ? 🤔

CM577 and ESOPEC trail #ASCO2024 ; CM577, DFS, randomization after Chemoradiotherapy; ESOPEC, PFS, randomization at the beginning. another issue : what is the impact of PD-L1 level ?

Chercheurs et médecins de toute la France alertent. Libertés, Tolérance, Éthique, Savoir: les valeurs de la Science et de la Médecine sont menacées. Ne tolérons pas le racisme, l’antisémitisme, la xénophobie. N’ayons pas peur de le dire. Nous regretterions de n avoir rien dit.

Or more patients included in phase 2 trials, less patients highly selected, and efficacy parameters less good.

Chemo + osi ?

Thank you for the invitation Pr Nawfel MELLAS , it's always a great pleasure to come and talk about thoracic oncology in Morocco! We start the day with digestive cancer and a superb presentation by Pr Bennouna Jaafar Hôpital Foch on Colorectal Cancer.

Great presentation, peri-operative therapeutics in NSCLC d.planchard , Fez, Morocco, many questions, some answers. Thank you for discussion.

Next on the ESMO preceptorship list...we'll be waiting for you tomorrow in Paris to talk about the lung ! Solange Peters ESMO - Eur. Oncology

ESMO preceptorships always high interactive sessions, thank you for being here d.planchard Solange Peters

ESMO preceptorship Paris Lung Cancer thank you ⁦d.planchard⁩ ⁦Solange Peters⁩

Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm An excellent review👇 nature.com/articles/s4157…

The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy. Read the full CheckMate 8HW trial results: nej.md/4eGp1tj